Palbo Capsule 125 mg contains Palbociclib, a targeted cancer therapy used primarily for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Palbociclib is classified as a cyclin-dependent kinase (CDK) 4/6 inhibitor, which works by blocking the activity of CDK4 and CDK6 enzymes, essential for cancer cell proliferation. By inhibiting these enzymes, Palbociclib arrests the cell cycle in the G1 phase, preventing cancer cells from dividing and slowing tumor growth.

This oral capsule formulation provides a convenient and precise dosing option, enabling patients to receive effective therapy in an outpatient setting. Palbo Capsule 125 mg is usually administered in combination with endocrine therapy such as letrozole or fulvestrant, enhancing its efficacy in hormone receptor-positive breast cancer.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Palbo Capsule 125 mg is indicated for:

• HR+/HER2- advanced or metastatic breast cancer in postmenopausal women.

• Combination therapy with aromatase inhibitors or fulvestrant to improve progression-free survival.

• Patients with advanced disease who are not candidates for chemotherapy or require targeted oral therapy.

It is not recommended for patients with HER2-positive tumors, other types of malignancies without CDK4/6 involvement, or severe hepatic impairment unless specifically advised by an oncologist.

Key Benefits

• Targeted cancer therapy: Specifically inhibits CDK4/6 enzymes involved in tumor cell proliferation.

• Slows tumor progression: Helps control disease in advanced or metastatic breast cancer.

• Combination therapy: Enhances the effectiveness of endocrine therapies for improved patient outcomes.

• Oral administration: Convenient, outpatient-friendly therapy without the need for intravenous infusions.

• Proven efficacy: Clinical trials demonstrate significant improvements in progression-free survival and delayed disease progression.

Palbo Capsule 125 mg offers a precision medicine approach for breast cancer patients, allowing treatment to focus on the molecular drivers of tumor growth.

Dosage and Administration

• Recommended dose: 125 mg orally once daily for 21 consecutive days, followed by 7 days off treatment to complete a 28-day cycle.

• Take capsules at the same time each day, with or without food.

• Swallow capsules whole; do not crush, chew, or open them.

• Monitor blood counts regularly, as Palbociclib may cause neutropenia or other hematologic effects.

• Dose adjustments may be necessary for patients experiencing severe adverse effects or liver dysfunction.

Adherence to the prescribed schedule is crucial to maximize efficacy and minimize side effects.

Precautions

• Avoid in patients with severe hepatic impairment or known hypersensitivity to Palbociclib.

• Monitor for hematologic toxicities including neutropenia, leukopenia, anemia, and thrombocytopenia.

• Use with caution in patients with pre-existing infections, liver disease, or gastrointestinal disorders.

• Inform your physician about all concurrent medications, as Palbociclib may interact with CYP3A inhibitors or inducers.

• Effective contraception is recommended during treatment due to potential teratogenicity.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Palbo Capsule 125 mg is generally well tolerated under supervision. Common side effects include:

• Neutropenia and other blood count abnormalities

• Fatigue and weakness

• Nausea, diarrhea, or vomiting

• Hair thinning or alopecia

• Mouth sores or stomatitis

Serious but rare effects may include severe infections, liver dysfunction, or pulmonary embolism. Immediate medical attention is required if severe symptoms develop.

Storage Instructions

• Store at below 25°C in a cool, dry place.

• Protect capsules from moisture and light.

• Keep out of reach of children.

• Do not use after the expiration date on the packaging.

Palbo Capsule 125 mg (Palbociclib) is a safe, targeted, and effective therapy for HR+/HER2- advanced or metastatic breast cancer, providing improved disease control and better patient outcomes when used as part of combination endocrine therapy.